zanamivir karen libby zanamivir general description zanamivir generic name relenza is an orally inhaled antiviral effective for the treatment of influenza a or b infections in adults it is also under investigation for influenza prophylaxis mechanism zanamivir inhibits influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release indications indicated for treatment of uncomplicated influenza in adults and adolescents 12 years and older who have been symptomatic for no more than 2 days usage dosage the recommended dosage for treatment of influenza in patients over 12 years of age is 2 doses of 5 mg each for a total dose of 10 mg twice daily approximately 12 hours apart for 5 days two doses should be taken on the first day of treatment whenever possible provided there is at least 2 hours between doses on subsequent days doses should be about 12 hours apart eg morning and evening at approximately the same time each day precautions zanamivir use should be avoided if the patient is undergoing any concurrent use of inhaled medications or the patient is pregnant or breastfeeding also it is important to initiate treatment early for efficacy ie within 48 hours contraindications zanamivir is contraindicated in patients with a known hypersensitivity to any component of the formulation it has not been evaluated in high risk patient groups potential adverse effects adverse effects are well tolerated no serious adverse events have been observed sources http www relenza com http www glaxowellcome com
